Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Shares Outstanding (Weighted Average) (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Shares Outstanding (Weighted Average) readings, the most recent being $308.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.31% to $308.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $308.4 million, a 1.31% increase, with the full-year FY2025 number at $308.4 million, up 1.31% from a year prior.
  • Shares Outstanding (Weighted Average) hit $308.4 million in Q4 2025 for Amicus Therapeutics, roughly flat from $308.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $308.4 million in Q4 2025 to a low of $265.4 million in Q2 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $299.0 million (2023), compared with a mean of $295.8 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 6.5% in 2022 and later grew 0.99% in 2023.
  • Amicus Therapeutics' Shares Outstanding (Weighted Average) stood at $271.4 million in 2021, then rose by 6.5% to $289.1 million in 2022, then increased by 2.11% to $295.2 million in 2023, then increased by 3.12% to $304.4 million in 2024, then increased by 1.31% to $308.4 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $308.4 million (Q4 2025), $308.1 million (Q3 2025), and $308.0 million (Q2 2025) per Business Quant data.